STOCK TITAN

Neuronetics (STIM) Financials

STIM NASDAQ
Trailing 12 months to September 30, 2026
Revenue $159.8M +23.0% YoY
Net Income -$23.1M n/m YoY
EPS (Diluted) -$0.33 n/m YoY
Free Cash Flow -$9.6M n/m YoY
Market Cap $120.6M as of Nov 20, 2026
Price / Sales 0.8x on $159.8M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 6.4x on $18.7M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the STIM SEC filings page.

Neuronetics, Inc. (STIM) reported $159.8M in revenue over the twelve months to Sep 30, 2026, up 23.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI STIM FY2025

FY2025 shows a business where sales nearly doubled, but gross-margin compression and heavier debt still leave cash generation negative.

Revenue rose 99.2%, but cost of revenue rose 270.7%, so the sales surge did not translate into proportionate gross profit. Operating margin improved 25.1 percentage points while SG&A rose only 27.9%, indicating sales growth absorbed overhead even though the gross-profit conversion weakened.

Liabilities were 81.5% of assets in FY2025, up from 70.5% in FY2023, placing more of the asset base ahead of shareholders. Equity fell 34.5% across that span while debt-to-equity reached 2.9x, making expansion more dependent on liabilities.

FY2025 operating cash flow was -$20.4M and free cash flow was -$21.2M, so the deficit was not mainly a heavy investment cycle. Capital expenditures were only 0.5% of revenue, while reported liquidity equaled 16.6 months of annual operating outflow; cash availability and cash generation are distinct measures.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 43 / 100
Financial Health Score 43/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Neuronetics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
43

Neuronetics, Inc. held $28.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $20.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Neuronetics, Inc. scores 43/100 among other emerging companies.

Dilution
22

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Neuronetics, Inc. scores 22/100 on it among other emerging companies.

R&D Intensity
21

Neuronetics, Inc. spent $6.6M on research and development in fiscal year 2025, which was 3.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Neuronetics, Inc. scores 21/100 among other emerging companies.

Revenue Progress
76

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Neuronetics, Inc. scores 76/100 on it among other emerging companies.

Burn Trend
68

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Neuronetics, Inc. scores 68/100 on it among other emerging companies.

Balance Sheet
30

Neuronetics, Inc.'s cash, cash equivalents and investments came to $28.1M at the end of fiscal year 2025, against $115.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Neuronetics, Inc. scores 30/100 among other emerging companies.

Altman Z-Score Distress
-3.33

Neuronetics, Inc. scores -3.33, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $458.8M against total assets of $141.6M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
4/9

Neuronetics, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality No Cash Backing
N/A

Neuronetics, Inc. reported a net loss of $39.0M while operations used $20.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Neuronetics, Inc. reported an operating loss of $31.4M against $7.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$42.0M
YoY+12.5%
QoQ+0.9%
5Y CAGR+24.9%

Neuronetics, Inc. generated $42.0M in revenue in Q3 2026. This represents an increase of 12.5% from the same quarter a year earlier. Against the prior quarter it is up 0.9%.

EBITDA
$1.3M
YoYn/m
QoQn/m
5Y CAGRn/m

Neuronetics, Inc.'s EBITDA was $1.3M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$1.7M
YoYn/m
QoQn/m
5Y CAGRn/m

Neuronetics, Inc. reported a net loss of $1.7M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.02
YoYn/m
QoQn/m

Neuronetics, Inc. earned -$0.02 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
$768K
YoYn/m
QoQn/m
5Y CAGRn/m

Neuronetics, Inc. generated $768K in free cash flow in Q3 2026, representing cash available after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$22.1M
YoY-21.0%
QoQ+15.2%
5Y CAGR-26.0%

Neuronetics, Inc. held $22.1M in cash against $61.8M in long-term debt as of Q3 2026.

Shares Outstanding
78M
YoY+13.5%
QoQ+2.0%

Neuronetics, Inc. had 78M shares outstanding in Q3 2026. This represents an increase of 13.5% from the same quarter a year earlier. Against the prior quarter it is up 2.0%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
52.2%
YoY+6.3pp
QoQ+1.1pp
5Y change-25.0pp

Neuronetics, Inc.'s gross margin was 52.2% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 6.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.

Operating Margin
1.3%
YoY+20.9pp
QoQ+4.9pp
5Y change+53.3pp

Neuronetics, Inc.'s operating margin was 1.3% in Q3 2026, reflecting core business profitability. This is up 20.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.9 percentage points.

Net Margin
-4.0%
YoY+20.2pp
QoQ+4.2pp
5Y change+55.0pp

Neuronetics, Inc.'s net profit margin was -4.0% in Q3 2026, showing the share of revenue converted to profit. This is up 20.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.2 percentage points.

Return on Equity
-9.0%
YoY+24.0pp
QoQ+10.2pp
5Y change-0.1pp

Neuronetics, Inc.'s quarterly ROE was -9.0% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 24.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.2 percentage points.

Capital Allocation

R&D Spending
$1.2M
YoY-20.9%
QoQ-10.9%
5Y CAGR-5.5%

Neuronetics, Inc. invested $1.2M in research and development in Q3 2026. This represents a decrease of 20.9% from the same quarter a year earlier. Against the prior quarter it is down 10.9%.

Capital Expenditures
$470K
YoY+312.3%
QoQ+12.7%
5Y CAGR+1.1%

Neuronetics, Inc. invested $470K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 312.3% from the same quarter a year earlier. Against the prior quarter it is up 12.7%.

Share Buybacks

Not reported for Q3 2026.

STIM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

STIM quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$42.0M+12.5%$41.6M+9.1%$34.5M+7.8%$41.8M+85.7%$37.3M+101.3%$38.1M+131.7%$32.0M+83.6%$22.5M+8.0%
Cost of Revenue$20.1M-0.6%$20.3M0.0%$18.3M+12.7%$20.1M+164.1%$20.2M+345.8%$20.4M+376.5%$16.2M+275.1%$7.6M+67.3%
Gross Profit$21.9M+28.0%$21.2M+19.5%$16.2M+2.6%$21.7M+45.7%$17.1M+22.2%$17.8M+45.8%$15.7M+20.2%$14.9M-48.0%
R&D Expenses$1.2M-20.9%$1.3M-25.7%$1.4M-15.6%$1.7M-71.1%$1.5M-37.7%$1.8M-19.6%$1.6M-31.2%$5.8M+36.6%
SG&A Expenses$20.2M-12.1%$21.4M-11.0%$23.8M-5.4%$25.1M-25.4%$22.9M+18.7%$24.0M+30.2%$25.1M+42.8%$33.6M+10.3%
Operating Income$541Kn/m-$1.5Mn/m-$9.0Mn/m-$5.0Mn/m-$7.3Mn/m-$8.1Mn/m-$11.0Mn/m-$11.5Mn/m
EBITDA$1.3Mn/m-$772Kn/m-$8.3Mn/m-$4.3Mn/m-$6.4Mn/m-$7.2Mn/m-$10.1Mn/m-$11.0Mn/m
Interest Expense$1.9M-5.0%$1.9M+5.6%$2.0M+17.6%$2.1M+40.0%$2.0M+25.0%$1.8M+5.9%$1.7M0.0%$1.5M-6.3%
Net Income-$1.7Mn/m-$3.4Mn/m-$10.8Mn/m-$7.2Mn/m-$9.0Mn/m-$10.1Mn/m-$12.7Mn/m-$12.7Mn/m
EPS (Basic)-$0.02n/m-$0.05n/m-$0.16n/m-$0.10-$0.13-$0.15-$0.21-$0.46
EPS (Diluted)-$0.02n/m-$0.05n/m-$0.16n/m-$0.10-$0.13-$0.15-$0.21-$0.46
Diluted Shares (Avg)77M+14.4%73M+10.5%70M+13.2%N/A67M66M61MN/A

Not reported in any period shown, so not listed: Income Tax.

STIM Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

STIM quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$132.0M-9.3%$131.5M-2.3%$125.4M-11.7%$141.6M+0.5%$145.5M+96.3%$134.7M+39.1%$142.0M+36.8%$140.9M+21.6%
Current Assets$53.9M-17.0%$53.2M-5.2%$47.2M-22.2%$61.6M+5.9%$64.9M+21.4%$56.1M-25.6%$60.7M-25.9%$58.1M-38.0%
Cash & Equivalents$22.1M-21.0%$19.2M+75.0%$13.2M-34.7%$28.1M+52.4%$28.0M+34.0%$11.0M-74.3%$20.2M-57.6%$18.5M-69.1%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Inventory$4.9M+14.4%$5.5M+11.3%$4.7M+15.9%$4.3M+1.9%$4.3M-12.9%$4.9M-19.5%$4.1M-39.2%$4.2M-47.5%
Accounts Receivable$14.4M-22.8%$16.0M-38.9%$15.8M-39.7%$16.5M-29.5%$18.7M+11.1%$26.1M+52.3%$26.2M+49.7%$23.4M+48.0%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$23.6M+4.2%$23.6M+23.8%$23.6M+26.8%$23.6M+26.8%$22.7M$19.1M$18.6M$18.6M
Total Liabilities$109.6M-4.0%$109.9M+6.5%$108.4M+5.8%$115.3M+5.7%$114.1M+76.3%$103.1M+33.2%$102.5M+34.5%$109.1M+33.6%
Current Liabilities$26.9M-7.2%$28.3M+1.8%$28.3M+13.9%$30.5M-2.4%$28.9M+71.3%$27.8M-5.0%$24.8M+71.3%$31.3M+57.8%
Non-Current Liabilities$82.7M-2.9%$81.6M+8.3%$80.1M+3.2%$84.8M+8.9%$85.2M+78.0%$75.3M+56.4%$77.6M+25.9%$77.8M+25.9%
Long-Term Debt$61.8M-6.0%$61.5M+10.8%$61.3M+10.8%$65.8M+19.3%$65.7M+42.8%$55.5M+20.4%$55.3M-6.9%$55.2M-7.0%
Total Equity$18.7M-31.6%$17.9M-34.2%$13.3M-62.6%$22.4M-19.2%$27.4M+191.6%$27.1M+40.0%$35.5M+28.2%$27.7M-19.0%
Retained Earnings-$474.8Mn/m-$473.2Mn/m-$469.6Mn/m-$458.8Mn/m-$451.6Mn/m-$442.6Mn/m-$432.5Mn/m-$419.8Mn/m

STIM Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

STIM quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$1.2Mn/m-$1.0Mn/m-$9.4Mn/m$882Kn/m-$785Kn/m-$3.5Mn/m-$17.0Mn/m-$8.6M-503.0%
Depreciation & Amortization$742K-16.3%$729K-19.1%$745K-18.2%$767K+72.0%$886K+73.0%$901K+62.3%$911K+62.7%$446K-11.3%
Stock-Based Compensation$178K-87.4%$688K-62.1%$1.7M+16.1%N/A$1.4M-0.7%$1.8M+16.1%$1.4M+7.9%N/A
Capital Expenditures$470K+312.3%$417K+65.5%$197K-10.0%$216K+142.7%$114K-70.5%$252K-59.1%$219K-41.6%$89K-89.9%
Free Cash Flow$768Kn/m-$1.4Mn/m-$9.6Mn/m$666Kn/m-$899Kn/m-$3.8Mn/m-$17.2Mn/m-$8.7Mn/m
Investing Cash Flow-$470Kn/m-$417Kn/m-$172Kn/m-$216Kn/m-$114K-914.3%-$252Kn/m-$219K-422.1%-$2.4Mn/m
Financing Cash Flow$2.1M-88.0%$7.4M+740700.0%-$5.6M-129.4%-$1.0M-110.8%$17.9M$1K$19.0M$9.6M-57.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

STIM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

STIM quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin52.2%+6.3pp51.1%+4.5pp46.9%-2.3pp51.9%-14.3pp45.9%-29.7pp46.6%-27.4pp49.2%-25.9pp66.2%
Operating Margin1.3%+20.9pp-3.6%+17.5pp-26.1%+8.3pp-12.1%+38.9pp-19.6%+22.1pp-21.1%+30.6pp-34.4%+4.9pp-51.0%-29.7pp
Net Margin-4.0%+20.2pp-8.3%+18.3pp-31.3%+8.3pp-17.1%+39.2pp-24.3%+47.8pp-26.6%+33.2pp-39.6%+5.6pp-56.3%-50.2pp
Return on Equity-9.0%+24.0pp-19.3%+18.0pp-81.3%-45.6pp-32.0%+13.7pp-33.1%+109.1pp-37.3%+13.4pp-35.8%-7.3pp-45.7%-42.0pp
Return on Assets-1.3%+4.9pp-2.6%+4.9pp-8.6%+0.3pp-5.1%+3.9pp-6.2%+11.8pp-7.5%+2.6pp-8.9%-1.3pp-9.0%-7.9pp
Current Ratio2.01-0.2x1.88-0.1x1.67-0.8x2.02+0.2x2.24-0.9x2.02-0.6x2.44-3.2x1.86-2.9x
Debt-to-Equity3.30+0.9x3.45+1.4x4.62+3.1x2.94+1.0x2.40-2.5x2.05-0.3x1.56-0.6x1.99+0.3x
Liabilities-to-Equity5.86+1.7x6.16+2.4x8.17+5.3x5.15+1.2x4.17-2.7x3.80-0.2x2.89+0.1x3.94+1.5x
Asset Turnover0.32+0.1x0.320.0x0.270.0x0.30+0.1x0.260.0x0.28+0.1x0.23+0.1x0.160.0x
FCF Margin1.8%+4.2pp-3.4%+6.4pp-27.9%+25.9pp1.6%+40.2pp-2.4%+28.9pp-9.9%+24.1pp-53.8%+17.3pp-38.6%+29.3pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Neuronetics, Inc. STIM FY2025 $149.2M -$39.0M -26.2% $120.6M 43/100
Pulmonx Corporation LUNG FY2025 $90.5M -$54.0M -59.7% $111.9M 57/100
TriSalus Life Sciences, Inc. TLSI FY2025 $45.2M -$39.2M -86.9% $143.1M 51/100
Inogen Inc INGN FY2025 $348.7M -$22.7M -6.5% $137.8M 41/100
MaxCyte, Inc. MXCT FY2025 $33.0M -$44.6M N/A $141.5M 59/100
Apyx Medical Corporation APYX FY2025 $52.8M -$11.2M -21.2% $101.1M 46/100

Frequently Asked Questions

Neuronetics, Inc. (STIM) reported $149.2M in total revenue for fiscal year 2025. This represents a 99.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Neuronetics, Inc. (STIM) revenue grew by 99.2% year-over-year, from $74.9M to $149.2M in fiscal year 2025.

No, Neuronetics, Inc. (STIM) reported a net loss of $23.1M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $39.0M, with a net profit margin of -26.2%.

Neuronetics, Inc. (STIM) reported diluted earnings per share of -$0.59 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Neuronetics, Inc. (STIM) had EBITDA of -$28.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Neuronetics, Inc. (STIM) had $28.1M in cash and equivalents against $65.8M in long-term debt.

Neuronetics, Inc. (STIM) had a gross margin of 48.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Neuronetics, Inc. (STIM) had an operating margin of -21.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Neuronetics, Inc. (STIM) had a net profit margin of -26.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Neuronetics, Inc. (STIM) has a return on equity of -174.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Neuronetics, Inc. (STIM) recorded an outflow of $21.2M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Neuronetics, Inc. (STIM) recorded an outflow of $20.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Neuronetics, Inc. (STIM) had $141.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Neuronetics, Inc. (STIM) invested $801K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Neuronetics, Inc. (STIM) invested $6.6M in research and development during fiscal year 2025.

Neuronetics, Inc. (STIM) had 69M shares outstanding as of fiscal year 2025.

Neuronetics, Inc. (STIM) had a current ratio of 2.02 as of fiscal year 2025, which is generally considered healthy.

Neuronetics, Inc. (STIM) had a debt-to-equity ratio of 2.94 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Neuronetics, Inc. (STIM) had a liabilities-to-equity ratio of 5.15 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Neuronetics, Inc. (STIM) had a return on assets of -27.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Neuronetics, Inc. (STIM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $120.6M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Neuronetics, Inc. (STIM) trades at 0.8x sales, its market capitalization divided by $159.8M revenue, trailing 12 months to September 30, 2026. The market capitalization is $120.6M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Neuronetics, Inc. (STIM) held $28.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $20.4M over that year. Dividing the one by the other, the reported balance equals about 17 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Neuronetics, Inc. (STIM) has an Altman Z-Score of -3.33, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Neuronetics, Inc. (STIM) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Neuronetics, Inc. (STIM) reported a net loss of $39.0M while operations used $20.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Neuronetics, Inc. (STIM) reported an operating loss of $31.4M against $7.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Neuronetics, Inc. (STIM) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top